Researchers developing 'homing beacon drugs' to target cancer cells

Nov 20, 2012

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nanotechnology.

John Lewis, the Frank and Carla Sojonky Chair in Research with the Faculty of & Dentistry, published his findings in the peer-reviewed journal, Nano Letters. He is also an associate professor in the Department of Oncology, a Fellow with the National Institute for Nanotechnology at the U of A and director of the Translational Prostate Cancer Research Group.

Lewis noted chemotherapy goes through the body and kills any cells that are dividing, even healthy ones – which is why cancer patients have immune system problems, hair loss, nausea and skin problems.

"We are developing smart drugs that determine which are the cancer cells and which aren't, then selectively kill only the cancer cells. The drugs look for a protein that is only found in cancer cells, not normal cells. This system acts like a homing beacon for tumours."

These drugs, tested to date in only animal lab models, could be used within a week of cancer diagnoses, predicts Lewis. The drugs would target cancerous cells throughout the body – attacking sneaky cancer cells that have already escaped and grown outside the site of the main tumour.

Lewis wasn't sure when these homing beacon drugs could be available for physicians to use with patients, but hopes his works paves the way for patient-centered therapies.

"If we can use 'smart' drugs that home in on tumours, we can dramatically decrease side effects for patients, lower the chance of recurrence, and hopefully increase the cancer survival rate."

Meanwhile, Lewis and his research team are continuing their work on trying to figure out what causes cancer cells to escape and spread from the main tumour site because the cells that move are different than the ones in the main tumour. They have pinpointed numerous genes that set these 'moving' cancer cells apart from the ones that stay put. Based on this research, they have come up with a that uses a 'tumour glue' to prevent these moving from breaking apart from the main tumour, which prevents the spread of the cancer. Using knowledge gained from the 'tumour glue' drug, Lewis and his team are working to develop new blood tests to predict whether prostate and other cancers will spread.

Explore further: Experts cautious over Google nanoparticle project

add to favorites email to friend print save as pdf

Related Stories

Research makes significant cancer breakthrough

Aug 08, 2012

(Medical Xpress) -- A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer. The discovery could see the development of new therapies, which ...

New treatment option for advanced prostate cancer

Aug 12, 2011

A successful interdisciplinary project is underway between two research groups, in which senior researcher Rebecka Hellsten and Professor Anders Bjartell at the Faculty of Medicine's division for Urological Cancer Research, ...

Possible new cancer treatment identified

Apr 19, 2012

New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study ...

Cancer treatment discovery opens tumours to immune cells

May 28, 2012

(Medical Xpress) -- Scientists at the Western Australian Institute for Medical Research (WAIMR) have made exciting progress in their quest to help patients fight cancer using the body's own immune system.The ...

Recommended for you

Nanosafety research: The quest for the gold standard

22 hours ago

Empa toxicologist Harald Krug has lambasted his colleagues in the journal Angewandte Chemie. He evaluated several thousand studies on the risks associated with nanoparticles and discovered no end of shortc ...

New nanodevice to improve cancer treatment monitoring

Oct 27, 2014

In less than a minute, a miniature device developed at the University of Montreal can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug. Just as accurate and ten ...

Molecular beacons shine light on how cells 'crawl'

Oct 24, 2014

Adherent cells, the kind that form the architecture of all multi-cellular organisms, are mechanically engineered with precise forces that allow them to move around and stick to things. Proteins called integrin ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.